The Effects of Inspiratory Muscle Training Female Patients With Fibromyalgia
Key facts
- Who runs it
- Nigde Omer Halisdemir University
- Where
- Niğde, TürkiyeSee the site
- Trial code
- Status
- Not yet recruiting
- People taking part
- 51 people, planned
- Started
- 5 Dec 2025
- Expected to end
- 5 Dec 2026
- Type of study
- Interventional, 3 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Exercise
- Record updated
- 3 December 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Be aged between 18 and 65 years old,
- Have been diagnosed with fibromyalgia according to the 2010/2016 ACR criteria,
- Be female,
- Have moderate pain lasting at least 3 months and defined as at least 30 mm on the 0-100 mm visual analogue scale (VAS)
Who cannot take part
- Current use of narcotic drugs,
- Presence of chronic heart disease,
- History of asthma or other chronic respiratory diseases,
- Diabetes, kidney, adrenal, pituitary or thyroid disorders,
- History of serious neurological or psychiatric disorders (e.g. mania, psychosis, suicidal tendencies, bipolar disorder, schizophrenia, autism spectrum disorders),
- Neurodegenerative diseases (e.g. Parkinson's, Alzheimer's, Huntington's disease),
- Presence of active cardiac implants
- Pregnancy,
- Head trauma, migraine,
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in Türkiye
- Niğde Ömer Halisdemir ÜniversitesiNiğde, TürkiyeContact: Gürkan Demirtaş, PhDNo longer taking part
About the trial
What the trial wants to find out
Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and psychological symptoms. Autonomic nervous system (ANS) dysfunction, marked by increased sympathetic and reduced parasympathetic activity, is considered one of its possible mechanisms. Although exercise is recommended in treatment, low motivation and fatigue often limit participation. Therefore, inspiratory muscle training (IMT), which targets the respiratory muscles, is seen as an easy-to-apply alternative.This randomized, controlled, double-blind study will be conducted at Niğde Ömer Halisdemir University Hospital. Fifty-one women aged 18-65 years who meet the 2010/2016 ACR criteria for fibromyalgia will be randomly assigned to three groups: training (30% of maximal inspiratory pressure), sham (0-10%), and control (no training). ANS functions will be assessed using heart rate variability and the COMPASS-31 questionnaire. Pain, sleep quality, fatigue, anxiety, depression, and respiratory muscle strength will also be evaluated. Training will be performed with the Powerbreathe® device twice daily for six weeks.The study aims to investigate the effects of IMT on ANS functions in fibromyalgia and to explore its relationship with symptoms such as pain, fatigue, sleep disturbances, anxiety, and depression.
The 3 groups in the trial
- Study GroupTreatment being tested
Training at 30% of maximum inspiratory pressure for 6 weeks, 2 sessions per day, 7 days a week
Treatment: Exercise
- Sham groupSham treatment, for comparison
Training at 0-10% of maximum inspiratory pressure for 6 weeks, 2 sessions per day, 7 days a week
Treatment: Exercise
- Control groupNo study treatment, for comparison
No Intervention
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Effects of Inspiratory Muscle Training on the Autonomic Nervous System and Clinical Symptoms in Female Patients With Fibromyalgia
- Fit questions
- Built from NCT07261696, who can take part
- Record updated
- 3 December 2025